Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.80
-0.49 (-2.54%)
At close: Apr 1, 2025, 4:00 PM
19.00
+0.20 (1.06%)
After-hours: Apr 1, 2025, 6:09 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
13.87B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SMMT News
- 8 days ago - Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga
- 11 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer - Business Wire
- 5 weeks ago - Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - PRNewsWire
- 5 weeks ago - Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program - Seeking Alpha
- 5 weeks ago - Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Pfizer: What The Summit Therapeutics Deal Brings - Seeking Alpha
- 5 weeks ago - Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024 - Business Wire